Initiate Phase 3 portion of the CAEL-101 program

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 30 Jan 2020
Due: 31 Dec 2020
Delivered: September 2020

Deadline
Met
Late
Not met
Today

What the company said

“the Phase 3 portion of the program planned to begin later in 2020, pending dose selection.”

SourceAlexion Pharmaceuticals Form 8-K press release, 2020-01-30
FilingSEC filing index
Deadline as statedlater in 2020
Deadline used31 Dec 2020, the last day of the stated period
TypeProject
Permanent referenceKI-C-2020-C899866-019371
Cite as https://keptindex.org/c/KI-C-2020-C899866-019371/ — this address never changes.

What we found

Evidence strength A What the grades mean

Alexion announced the initiation of the CARES program, which includes the Phase 3 trials for CAEL-101, in September 2020, meeting the commitment to initiate the program in 2020.

A
Alexion Pharmaceuticals 10-K filed 2021-02-08 Regulatory filing · published 8 Feb 2021 · retrieved 21 Oct 2026 · kept permanently by the SEC · fingerprint 10caf5605550
“In September 2020, Alexion and Caelum announced the initiation of the Cardiac Amyloid Reaching for Extended Survival (CARES) program. This includes two parallel Phase III trials to evaluate the survival benefits of CAEL-101.” ✓ confirmed on the page

Checked 21 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift -92 days
2 versions

Version 1 · original · stated 30 Jan 2020

Deadline 31 Dec 2020 (“later in 2020”) · wording expected
Version 2 · stated 30 Jul 2020

Deadline 30 Sep 2020 (“in the third quarter of 2020”) · wording expected

“the Phase 3 portion of the program is planned to begin in the third quarter of 2020, pending dose selection.”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Project other
Indicative materiality: Low rules
Action: Initiate
Deliverable: Phase 3 portion of CAEL-101 program
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Conditional: Yes: pending dose selection

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Alexion Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.